Aridis Pharmaceuticals

$5.68
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.43 (-7.04%) Today
$0.00 (0.00%) As of 9:00 PM UTC after-hours

Why Robinhood?

You can buy or sell ARDS and other stocks, options, and ETFs commission-free!

About ARDS

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA. The listed name for ARDS is Aridis Pharmaceuticals Inc. Common Stock.

CEO
Vu L. Truong
Employees
25
Headquarters
Los Gatos, California
Founded
2003
Market Cap
56.38M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
51.48K
High Today
$6.08
Low Today
$5.67
Open Price
$5.98
Volume
34.52K
52 Week High
$10.18
52 Week Low
$3.80

ARDS Earnings

-$1.03
-$0.69
-$0.34
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Apr 8, After Hours

You May Also Like

GB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure